LAMC2

Across TCGA pan-cancer cohorts, LAMC2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated LAMC2 data layer compared with 25 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher LAMC2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated LAMC2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and CCRCC show a favorable association.

LUAD, PDAC, and LSCC are the cancer types where LAMC2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.919	1.000	.001	54	view →
PDAC	OS	Tertile	All	0.437	0.646	.009	24	view →
LSCC	OS	Quartile	All	0.676	0.954	.014	12	view →
UCEC	DFS	Quartile	II,III,IV	1.000	0.464	.018	10	view →
HNSC	DFS	Median	IV	0.328	0.889	.014	2	view →
CCRCC	OS	Median	III,IV	1.000	0.801	.034	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

LAMC2–LUAD (OS)

Open the LUAD breakdown →